The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Por:
Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H
Publicada:
17 abr 2018
Categoría:
Oncology
Resumen:
Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly available. However, their clinical utility in guiding patients' treatment remains unknown. Here, we assessed whether molecular profiling helps physicians in therapeutic decision making by analysing the molecular profiles of 1057 advanced cancer patient samples after failing at least one standard of care treatment using a combination of next-generation sequencing (NGS), immunohistochemistry (IHC) and other specific tests. The resulting information was interpreted and personalized treatments for each patient were suggested. Our data showed that NGS alone provided the oncologist with useful information in 10-50% of cases (depending on cancer type), whereas the addition of IHC/other tests increased extensively the usefulness of the information provided. Using internet surveys, we investigated how therapy recommendations influenced treatment choice of the oncologist. For patients who were still alive after the provision of the molecular information (76.8%), 60.4% of their oncologists followed report recommendations. Most treatment decisions (93.4%) were made based on the combination of NGS and IHC/other tests, and an approved drug- rather than clinical trial enrolment- was the main treatment choice. Most common reasons given by physicians to explain the non-adherence to recommendations were drug availability and cost, which remain barriers to personalised precision medicine. Finally, we observed that 27% of patients treated with the suggested therapies had an overall survival 12 months. Our study demonstrates that the combination of NGS and IHC/other tests provides the most useful information in aiding treatment decisions by oncologists in routine clinical practice.
Filiaciones:
Laes JF:
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Aftimos P:
Institut Hospital del Mar d'Investigacions Médiques, Barcelona, Spain
Barthelemy P:
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Bellmunt J:
Institut Hospital del Mar d'Investigacions Médiques, Barcelona, Spain
Harvard University, Cambridge, Massachusetts, USA
Berchem G:
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
Camps C:
Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Peñas RL:
Consorcio Hospitalario Provincial de Castellón, Castellón, Spain
Finzel A:
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
García-Foncillas J:
Fundación Jimenez Díaz, IDC Salud, Madrid, Spain
Hervonen P:
Docrates Cancer Center, Helsinki, Finland
Wahid I:
Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Joensuu T:
Docrates Cancer Center, Helsinki, Finland
Kathan L:
Cancercare, Cape Town, South Africa
Kong A:
University Hospital Birmingham NHS Trust, University of Birmingham, Edgbaston, UK
Mackay J:
The London Breast Clinic, London, UK
Mikropoulos C:
Kent Oncology Centre, Kent, UK
Mokbel K:
The Princess Grace Hospital, London, UK
Mouysset JL:
Clinique Rambot-Provençale, Aix-en-Provence, France
Odarchenko S:
Vinnitsa Regional Clinical Oncology Center, Vinnitsa, Ukraine
Perren TJ:
St. James University Hospital, Leeds, UK
Pienaar R:
Cancercare, Cape Town, South Africa
Regonesi C:
Clinica Las Condes, Santiago, Chile
Alkhayyat SS:
King Abdulaziz University Hospital, Jeddah, Saudi Arabia
El Kinge AR:
Specialized Medical Center Hospital, Riyadh, Saudi Arabia
Abulkhair O:
Specialized Medical Center Hospital, Riyadh, Saudi Arabia
Galal KM:
Kasr El-Aini Hospital, Cairo University, Cairo, Egypt
Ghanem H:
Lebanese American University Medical Center-Rizk Hospital (LAUMC-RH), Beirut, Lebanon
El Karak F:
Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
Garcia A:
Nuffield Hospital, Chester, UK
Ghitti G:
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Sadik H:
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
|